Introduction: Every eye with central retinal vein occlusion (CRVO) is at risk for developing neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant monoclonal antibody binding all isoforms of VEGF. Several studies have demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation associated with NVG.
Introduction
Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic retinopathy with a cumulative 10-year incidence of 1.6% [1] . Central retinal vein occlusion (CRVO) is a disease of the elderly patients (age >50 years old). Major risk factors are hypertension, diabetes, and atherosclerosis. Other risk factors are glaucoma, syphilis, sarcoidosis, vasculitis, increased intraorbital or intraocular pressure, hyphema, hyperviscosity syndromes (polycythemia, multiple myeloma, Waldenstrom's macroglobulinemia, and leukemia), high homocysteine levels, sickle cell, and HIV [2] .
Every eye with CRVO is at risk for developing neovascular glaucoma (NVG). Lowering intraocular pressure helps to improve retinal circulation in an eye with CRVO [3] , and there is a 10% risk for development of RVO in the fellow eye [4] .
Risk factors for developing neovascular iris in patients with CRVO are the amount of nonperfused retina, extent of retinal hemorrhages, male sex, and central vein occlusion of less than one month duration [5] . Visual acuity in patients with CRVO at baseline is a strong predictor for the development of iris and angle neovascularisation, as is the amount of nonperfusion seen by fluorescein angiogram [6] .
Established modalities for the treatment of NVG include panretinal photocoagulation (PRP) to reduce the produc-tion of vasoproliferative factors by ischemic retina, and medical and surgical control of elevated intraocular pressure. Bevacizumab (Avastin; Genentech, San Francisco, CA) is a recombinant monoclonal antibody binding all isoforms of vascular endothelial growth factor (VEGF). Several studies have demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation associated with NVG with promising results [7] [8] [9] [10] [11] [12] [13] [14] .
We present a patient with history of age-related macular degeneration (AMD) and polycythemia vera who developed CRVO, which subsequently got complicated by NVG, and was successfully treated with intravitreal injection of Bevacizumab followed by PRP.
Case presentation
A 74 year old Caucasian female presented to the Eye clinic complaining of blurry vision in the right eye that started one week prior to presentation.
Past medical history is significant for hypertension, dyslipidemia, diabetes, and polycythemia vera. Past ocular history is significant for age related macular degeneration (AMD), cataract extraction and intraocular lens placement in both eyes. Most recent lab check showed hemoglobin of 16.5 gram per deciliter, and Hematocrit of 48.8%. 
Discussion
CRVO is characterized by vascular obstruction leading to intraretinal hemorrhage, exudation of fluid, and variable degrees of ischemia. The vascular damage associated with the occlusion is accompanied by complex cellular and inflammatory reactions. A disturbed balance of angiogenic and inflammatory cytokines in ocular fluid has been observed in RVO [15] [16] [17] [18] .
VEGF is a known chemoattractant for macrophages and monocytes, a key factor in angiogenesis and increased vascular permeability. VEGF stimulates neovascularization and the formation of macular edema in CRVO [19] . Funk et al. found an increased VEGF levels in the aqueous humor of patients with CRVO. They also demonstrated measurable levels of VEGF in the control group providing evidence for a physiological expression of this angiogenic factor in the human eye [18] . They supposed that cytokine levels in aqueous humor should reflect levels in the vitreous, as correlation of aqueous and vitreous levels has been described in the past [20] . Additionally, there has been no correlation between cytokine levels in the aqueous humor and in plasma [15, 20] , providing evidence for intraocular sources.
VEGF mRNA up-regulation has been observed in the human retina in patients with CRVO [21] as has a correlation of the severity of macular edema with aqueous and vitreous levels of VEGF [20] . Funk et al. concluded that initial monthly treatment with anti-VEGF in CRVO reduced VEGF levels to undetectable values and below physiologic levels. The changes of intraocular VEGF levels were also associated with disease activity [18] .
NVG secondary to CRVO is a devastating type of glaucoma with a poor prognosis. It is caused by neovascularisation of the iris and anterior chamber angle with eventual angle closure and intractable elevation of intraocular pressure (IOP) [14] .
The management of NVG includes lowering IOP (often surgically) and PRP, which reduces the production of vasoproliferative factors by ischaemic retina and can induce regression of anterior segment neovascularisation.
Bevacizumab is a neutralizing anti-VEGF recombinant humanized monoclonal antibody. Intravitreal bevacizumab is now a frequently used adjunct for the treatment of VEGF-mediated NVG in CRVO [7] [8] [9] [10] [11] [12] [13] [14] . Eyes treated with intravitreal bevacizumab should be monitored closely because surgery for IOP control and repeat bevacizumab injections are often necessary, regardless of initial angle status [14] . Bevacizumab should be instituted promptly after diagnosis, before irreversible anatomic and functional damage occurs [22] .
Ehlers et al. compared combination intravitreal bevacizumab/PRP for the treatment of NVG with PRP alone. They concluded that the combination treatment resulted in more rapid decrease in IOP. In addition, the combination group had increased frequency and rapidity of regression of neovascularization [23] .
Wakabayashi et al. studied 41 eyes with iris neovascularization (INV) or neovascular NVG secondary to ischemic retinal disorders. Patients received intravitreal Bevacizumab (1 mg) as the initial treatment for INV or NVG and were followed up for at least 6 months. Intravitreal bevacizumab was well tolerated, effectively stabilized INV activity, and controlled IOP in patients with INV alone and early-stage NVG without angle closure. In advanced NVG, Bevacizumab cannot control IOP but may be used adjunctively to improve subsequent surgical results [24] .
Conclusion
Our case illustrates an interesting presentation of CRVO in an old lady with multiple risk factors including polycythemia vera, hypertension, diabetes, and atherosclerosis. The patient progressed to an ischemic CRVO with secondary NVG. Her risk factors to develop NVG secondary to CRVO were the extent of retinal hemorrhages, CRVO of less than one month duration, and counting finger visual acuity upon initial presentation with CRVO. She was successfully treated with intravitreal Bevacizumab injection followed by PRP. The neovascularization regressed, and the intraocluar pressure was controlled.
In summary, our case report highlights the use of intravitreal Bevacizumab in combination with PRP in the treatment of NVG secondary to CRVO.
Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. There are moderate intraretinal hemorrhages throughout the posterior pole with a greater amount of hemorrhages in a peripapillary region. Mild disk edema appears to be present.
